TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06362681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Application of remineralizing agents on teeth and molars with MIH during 24 months of follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Application of remineralizing agents on teeth and molars with MIH during 24 months of follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Application of remineralizing agents on teeth and molars with MIH during 24 months of follow-up.
Study: NCT05577234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention
Description: The dog accompanied by the zootherapist will participate in the care of sessions 1 and 2. During these two sessions, the dog will be present with the child in the waiting room until the end of the dental consultation. Session 3 will take place without the dog being present.The usual management with conventional behavioural strategies and possible administration of MEOPA will be implemented during the 3 treatment sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Venham scale modified by Veerkamp
Description: The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Venham scale modified by Veerkamp
Description: The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
Study: NCT04691804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzuloparib , Abiraterone acetate and Prednisone
Description: 1. Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po~3. Prednisone tablets (strength: 5 mg) 5mg, Bid po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Description: 1. Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po~3. Prednisone tablets (strength: 5 mg)5mg, Bid po
Study: NCT05364788

Intervention type: OTHER
Intervention: Retrospective tissue sample analysis
Description: Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
Study: NCT06505447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daytime light exposure
Description: Participants will be exposed to a 10,000 lux light source within 3 feet of their face/eyes to promote the natural circadian rhythm for 2-3 hours from 10am to 12/1pm depending on their nap time at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daytime restricted feeding
Description: Participant's nutrition, parenteral or enteral, will be restricted to the hours when they are normally awake at home.
Study: NCT06150339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OASIS Walking Intervention
Description: Communication Care Plan, Sit to Stand Activity, Walking Program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OASIS Walking Intervention
Description: Communication Care Plan, Sit to Stand Activity, Walking Program
Study: NCT05983809

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Technological rehabilitation
Description: Specific rehabilitation for balance disorder using the robotic platform

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological rehabilitation
Description: Specific rehabilitation for balance disorder using the robotic platform
Study: NCT06313437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Menin inhibitor, 25 and 113 mg capsules, taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Menin inhibitor, 25 and 113 mg capsules, taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Kinase inhibitor, capsule taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Kinase inhibitor, capsule taken orally per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Antineoplastic agent, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Antineoplastic agent, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Antineoplastic agent, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
Study: NCT05356910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPPEN
Description: OPPEN training sessions (three small-group and two one-on-one sessions) build skills for effective peer PrEP outreach through didactic instruction, group discussions, role-play exercises, and goal planning and problem-solving activities.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Condition
Description: Control sessions (three small-group and two one-on-one sessions) build skills for diet and nutrition behavior change through didactic instruction, group discussions, and goal planning and problem-solving activities.
Study: NCT04874948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043
Description: Single oral administration of 14C-labeled radioactive 500mg BTZ-043
Study: NCT06653322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR-1703
Description: HR-1703 will be administered by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered by the SC injection.
Study: NCT06657326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom™ Ultra cobalt-chromium Biolimus A9™-coated stent
Description: Stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioFreedom™ stainless steel Biolimus A9™-coated stent
Description: Stent implantation
Study: NCT06474221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Based Psychosocial Intervention (EBPSI)
Description: Electronic based Psycho-social Intervention (EBPSI) described as video based telepsychiatry sessions targeted on brief intervention and coping skills; with a total of 5 sessions on days 10, 30, 45, 60 and 90 after baseline intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Based Psychosocial Intervention (EBPSI)
Description: Electronic based Psycho-social Intervention (EBPSI) described as video based telepsychiatry sessions targeted on brief intervention and coping skills; with a total of 5 sessions on days 10, 30, 45, 60 and 90 after baseline intervention.
Study: NCT05866419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThecaFlex DRx System
Description: The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
Study: NCT06670300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardonilimab
Description: Subjects will receive cardonilimab 10mg/kg once every three weeks; The maximum duration of administration is 2 years until disease progression or death, toxicity becomes intolerable, subject voluntarily requests withdrawal, or investigator determines that subject needs to withdraw from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardonilimab
Description: Subjects will receive cardonilimab 10mg/kg once every three weeks; The maximum duration of administration is 2 years until disease progression or death, toxicity becomes intolerable, subject voluntarily requests withdrawal, or investigator determines that subject needs to withdraw from the study.
Study: NCT06682208

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ES catheter
Description: ES catheter for postoperative pain control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve cryoablation (INC)
Description: INC used for postoperative pain control
Study: NCT06401447

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Simultaneously optimizing the target, dosage, and synchronized drugs for radiotherapy.
Study: NCT06686537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Patches
Description: Estradiol patched will be worn for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Patches
Description: Estradiol patched will be worn for 7 days.
Study: NCT06731959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flexlamose
Description: Fexlamose solution via nebulizer for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution via nebulizer for 28 days
Study: NCT06738394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Velocity Resistance Training
Description: High-velocity resistance training for patients with non-dialysis dependent chronic kidney disease Stages 4-5 with mobility limitations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention
Description: Dedicated contact, information, and motivation throughout the course of the study via weekly group sessions and informational handouts.
Study: NCT06741722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF
Description: The specific administration times and dosages for the DCMG chemotherapy regimen are as follows:~M: Mitoxantrone Hydrochloride Liposome Injection: 15 mg/m², IV, on Day 1, every 4 weeks (q4w); D: Decitabine: 20 mg/m², IV, Days 1-5, q4w; (or Azacitidine: 75 mg/m², IV, Days 1-7, q4w); C: Cytarabine: 100 mg, IV, every 12 hours on Days 1-5, q4w; For patients with hypoplastic bone marrow, the dose of cytarabine injection is 10 mg, every 12 hours, q4w; G: G-CSF: 5 μg/kg, subcutaneous injection, from Day 0 until the white blood cell count exceeds 10.0×10\^9/L, at which point chemotherapy is stopped; or Pegylated Recombinant Human Granulocyte Stimulating Factor Injection: 100 μg/kg, subcutaneous injection, on Day 0.~One cycle lasts for 4 weeks, with a planned administration of 1 or 2 cycles.
Study: NCT06741566

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal saline group
Description: 3 ml of saline 0.9 % twice daily for 2 days preoperatively at fixed time ( 9 am and 6 pm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin
Description: 20 IU of regular insulin on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal dexmedetomidine
Description: 1.5 mic/kg on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
Study: NCT06747650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Adolescents
Description: Standard of care (SOC) DBT-A includes approximately six weeks of pretreatment, and approximately six months of DBT-A skills group, individual therapy, and 24/7 phone coaching. During pre-treatment, clients are oriented to the DBT-A model and client commitment to treatment is established. After approximately six weeks, the client enters DBT-A skills group along with their caregiver. This skills group meets weekly for 1.5 hours and clinicians explain the five main DBT-A skills (mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path) via PowerPoints and discussion. Clients and their caregivers are assigned weekly homework. At the same time, teens are completing weekly 1-hour individual therapy sessions where they are utilizing the skills learned in group. Both teens and caregivers have access to what DBT-A calls 24/7 phone coaching. This phone coaching is 24/7 access to a therapist when a crisis is arising.
Study: NCT06751459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEMO Patch 2 - 14-day Monitoring
Description: A wearable ECG monitoring device used for continuous 14-day monitoring to detect atrial arrhythmias during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to assess early recurrence of atrial arrhythmias.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEMO Patch 2 - 1-day Monitoring
Description: A wearable ECG monitoring device used for 1-day monitoring during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to detect early recurrence of atrial arrhythmias.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEMO Link
Description: A supplementary ECG monitoring device used alongside MEMO Patch 2 during the 1st monitoring session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEMO Link
Description: A supplementary ECG monitoring device used alongside MEMO Patch 2 during the 1st monitoring session.
Study: NCT06754943

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A_Period 1
Description: * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B_Period 2
Description: * Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A_Period 3
Description: * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B_Period 4
Description: * Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B_Period 1
Description: * Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A_Period 2
Description: * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Study: NCT05453188

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental
Description: Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.
Study: NCT06754943

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment B_Period 3
Description: * Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment A_Period 4
Description: * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions
Study: NCT06755463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure education
Description: Participants will undergo acupressure therapy for 8 weeks, with twice-weekly sessions between 8:00 AM and 10:00 AM. A certified practitioner will train participants on target points, pressure techniques, frequency, and duration. Practical demonstrations will ensure correct application. Groups of up to 10 participants will be trained in a comfortable setting and practice techniques under supervision until proficient. The treatment protocol, based on literature, focuses on beta-endorphin and hypocretin levels, cognition, and patient-reported outcomes (pain, fatigue, depression, and quality of life). Participants will apply 3-5 kg pressure for 2 minutes per point at 12 symmetrical points (LI4, SP6, GV20, HT7, EX-HN3, LV3) using rhythmic movements, totaling 24 minutes. They will receive a diary to track home practices and a visual guide explaining each point's location and steps for application.
Study: NCT05453188

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Control
Description: Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.
Study: NCT04851990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To Better Days Large Patch
Description: Large patch containing vitamin D \& Dextrose for transdermal absorption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To Better Days Small Patch
Description: Small patch containing vitamin D \& Dextrose for transdermal absorption
Study: NCT06339385

Intervention type: BEHAVIORAL
Intervention: PADIS assessment
Description: Hospital and nursing records from the 24 hours preceding enrollment were examined to document the assessment rate of pain, agitation-sedation, and delirium.
Study: NCT05051696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H101
Description: Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
Study: NCT05202327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
Study: NCT06753071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine oral tablet
Description: Pyridostigmine oral tablet, 60 mg, twice daily, for 3 months
Study: NCT05202327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo contained corn starch.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contained corn starch.
Study: NCT05268185

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderna Booster Vaccine
Description: Participants assigned to this intervention will be given the recommendation to receive the Moderna vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, Moderna booster (0.25 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer Booster Vaccine
Description: Participants assigned to this intervention will be given the recommendation to receive the Pfizer vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, the Pfizer booster (0.30 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
Study: NCT06753071

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet, twice daily, for 3 months
Study: NCT06754332

Intervention type: DRUG
Group type: OTHER
Intervention: human chorionic gonadotropin
Description: The POI patients receive a single intramuscular injection of 10,000 units of human chorionic gonadotropin.